Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 202

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome

Open access
You, Sungyong, Knudsen, Beatrice S., Erho, Nicholas, Alshalalfa, Mohammed, Takhar, Mandeep, Al-deen Ashab, Hussam, Davicioni, Elai, Karnes, R. Jeffrey, Klein, Eric A., Den, Robert B., Ross, Ashley E., Schaeffer, Edward M., Garraway, Isla P., Kim, Jayoung, Freeman, Michael R. · 2016 · Cancer Research

Abstract

Prostate cancer is a biologically heterogeneous disease with variable molecular alterations underlying cancer initiation and progression. Despite recent advances in understanding prostate cancer heterogeneity, better methods for classification of prostate cancer are still needed to improve prognostic accuracy and therapeutic outcomes. In this study, we computationally assembled a large virtual cohort (n = 1,321) of human prostate cancer transcriptome profiles from 38 distinct cohorts and, using pathway activation signatures of known relevance to prostate cancer, developed a novel classification system consisting of three distinct subtypes (named PCS1–3). We validated this subtyping scheme in 10 independent patient cohorts and 19 laboratory models of prostate cancer, including cell lines and genetically engineered mouse models. Analysis of subtype-specific gene expression patterns in independent datasets derived from luminal and basal cell models provides evidence that PCS1 and PCS2 tumors reflect luminal subtypes, while PCS3 represents a basal subtype. We show that PCS1 tumors progress more rapidly to metastatic disease in comparison with PCS2 or PCS3, including PSC1 tumors of low Gleason grade. To apply this finding clinically, we developed a 37-gene panel that accurately assigns individual tumors to one of the three PCS subtypes. This panel was also applied to circulating tumor cells (CTC) and provided evidence that PCS1 CTCs may reflect enzalutamide resistance. In summary, PCS subtyping may improve accuracy in predicting the likelihood of clinical progression and permit treatment stratification at early and late disease stages. Cancer Res; 76(17); 4948–58. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-16-0902

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 202

Metadata

Authors
You, S., Knudsen, B. S., Erho, N., Alshalalfa, M., Takhar, M., Al-deen Ashab, H., Davicioni, E., Karnes, R. J., Klein, E. A., Den, R. B., Ross, A. E., Schaeffer, E. M., Garraway, I. P., Kim, J., & Freeman, M. R.
Venue
Cancer Research
Published
2016-08-31
Volume
76
Issue
17
Pages
4948-4958
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2431963657
Cited by
202
References
6
FWCI
14.30
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. https://app.cochat.ai/papers/10.1158/0008-5472.can-16-0902
The paper
You, S., Knudsen, B. S., Erho, N., Alshalalfa, M., Takhar, M., Al-deen Ashab, H., Davicioni, E., Karnes, R. J., Klein, E. A., Den, R. B., Ross, A. E., Schaeffer, E. M., Garraway, I. P., Kim, J., & Freeman, M. R. (2016). Integrated Classification of Prostate Cancer Reveals a Novel Luminal Subtype with Poor Outcome. Cancer Research. https://doi.org/10.1158/0008-5472.can-16-0902

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.